ArticleAmerican journal of ophthalmology case reports2026
Transient myopia induced by acetazolamide in a pregnant patient with idiopathic intracranial hypertension: A case of successful rechallenge.
Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acetazolamide is the mainstay of treatment for idiopathic intracranial hypertension (IIH). Transient myopia is a rare ocular adverse effect, usually attributed to ciliary body edema and forward displacement of the lens-iris diaphragm. Case presentation: A 44-year-old woman developed IIH during pregnancy following hormonal therapy for in-vitro fertilization. She was started on acetazolamide 1 g/day and, after five doses, experienced sudden bilateral blurred vision that improved with myopic correction and resolved spontaneously within 24 hours after discontinuation of acetazolamide. Examination showed no signs of angle closure or choroidal effusion. Optical coherence tomography (OCT) confirmed preserved ganglion cell layer and no axonal loss. After counselling the patient about the potential for recurrent transient myopia and other acetazolamide-related adverse effects, acetazolamide was reintroduced at a lower dose (500 mg/day). No recurrence of myopia occurred, and papilledema improved markedly over six weeks. Conclusion: This case illustrates a rare idiosyncratic effect of acetazolamide in pregnancy-associated IIH and demonstrates that rechallenge at a lower dose may be tolerated without recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.